<DOC>
	<DOCNO>NCT02531178</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , placebo-controlled , multiple dose study design assess safety , tolerability , pharmacokinetics , immunogenicity different dose level ABBV-257 give methotrexate . ABBV-257 placebo administer every week ( EOW ) total 4 dos . Subjects continue stable dose methotrexate weekly throughout participation study . This study conduct approximately 24 subject 3 dose group , 8 subject per group . Within group , 6 subject randomize receive ABBV-257 2 subject receive placebo . Subjects participate one dose group ineligible participate another dose group study .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics Multiple Subcutaneous Injections ABBV-257 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>Multiple dose study design assess safety , tolerability , pharmacokinetics , immunogenicity different dose level ABBV-257 give methotrexate .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis base 2010 American College Rheumatology ( ACR ) /European League Rheumatism ( EULAR ) criterion , ACR 1987 patient diagnosis prior 2011 ≥ 3 month . Except methotrexate ( MTX ) , subject must discontinue disease modify antirheumatic drug ( DMARD ) least 5 halflives first dose study drug , undergone cholestyramine washout receive Leflunomide within past 3 month . Subject must MTX therapy &gt; 3 month stable dose ( 7.5 25 mg/week ) , least 4 week prior first dose study drug . Subject must able continue stable dose MTX duration study participation . Body Mass Index ( BMI ) 19 35 , inclusive . ( BMI calculate weight [ kg ] divide height [ m2 ] . ) Judged good general health determine Investigator base upon result medical history , laboratory profile , physical examination 12lead electrocardiogram ( ECG ) perform screen Evidence antiABBV257 antibody result prestudy serum sample . History significant allergic reaction significant sensitivity constituent study drug ; history anaphylactic reaction agent ( e.g. , food product bee sting ) ; history major reaction Immunoglobulin G ( IgG ) contain product . History persistent chronic active infection ( ) require hospitalization treatment intravenous oral antimicrobials/antibiotics within 30 day prior initial study drug administration . History evidence active tuberculosis ( TB ) subject evidence risk factor latent TB . Clinically significant abnormal screen laboratory result evaluate Investigator , include serum value Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) great 2.25 × upper limit normal , creatinine great 1.5 × upper limit normal , absolute neutrophil count &lt; 1500 μ/L . Subject medical condition illness RA well control treatment would , opinion investigator , preclude study participation interfere symptoms Rheumatoid Arthritis ( RA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>